Objective: The objective of this study is to create a self-microemulsifying drug delivery system (SMEDDS) that will increase the solubility and bioavailability of a Biopharmaceutical Classification System -II (BCS-II) drug. Cinnarizine (CEN) is derivative of piperazine antihistamine drug with a low solubility and bioavailability. It was intended to improve the solubility and oral bioavailability of cinnarizine by creating a selfmicroemulsifying drug delivery system (SMEDDS). Methodology: The solubility of cinnarizine was tested with a various of oils, surfactants, and cosurfactants. On the basis of capacity to emulsify oils, surfactants were further screened. Campul MCM, Tween 80 and gelucire 41/14 was chosen as the oil, surfactant and co-surfactant in SMEDDS formulation. The microemulsion area was identified by plotting pseudoternary phase diagrams with water. Robustness to dilution, emulsification time, phase separation, droplet size, zeta potential and other factors were assessed for the prepared SMEDDS formulations. Results: The formulation F-1 to F-3 of cinnarizine are containing campul MCM, Tween 80 and gelucire 44/14 was converted into SMEDDS in different ratio of oil and surfactant cosurfactant mixture. The formulation has globules size range 95.70 to 101.21nm, zeta potential -23.2 to -28.6mV. The vitro dissolution profile was studied in 0.1 N HCl and phosphate buffer (pH 6.8) 95.27 to 89.32%. SMEDDS with S/CoS ratio (2:1) and S/CoS oil ratio (9:1) showed the highest drug release and thermodynamically stable Conclusion: Selfmicroemulsifying formulation of cinnarizine was successfully developed improved solubility and dissolution in comparison to pure drug, thus can serve as potential alternative to existing oral formulations..
Keywords: Solubility, Bioavailability, Dissolution, Globule size and Zeta potential.
How to cite this article: Prasad H, Rawat AKS, Development And In Vitro Of Characterization Novel Selfmicroemulsifying Drug Delivery System Of Low Solubility Drug Cinnarizine By Improved Bioavailability .Int J Drug Deliv Technol. 2026;16(1s): 152-159; DOI: 10.25258/ijddt.16. 152-159